European Journal of Heart Failure, Год журнала: 2025, Номер unknown
Опубликована: Июнь 2, 2025
Язык: Английский
Cardiovascular Diabetology, Год журнала: 2025, Номер 24(1)
Опубликована: Март 8, 2025
Coronary artery disease (CAD) and diabetes mellitus (DM) can induce changes in myocardial structure function, thereby increasing the risk of heart failure (HF). We aimed to identify alterations echocardiographic variables circulating biomarkers associated with DM, CAD, or both assess effect spironolactone on them. The "Heart OMics AGEing" (HOMAGE) trial evaluated markers fibrosis over 9 months follow-up people at for HF. From initial population (N = 527) HOMAGE trial, a total 495 participants (mean age 74 years, 25% women) were categorized according clinical phenotype (DM-/CAD + vs. DM+/CAD- DM+/CAD+), while DM-/CAD- group was excluded due low sample size 32). Multivariable linear regression analysis used relations between DM/CAD status. At baseline, whether not they had showed lower type I collagen synthesis (procollagen C-terminal propeptide; β [95% CI]: DM+/CAD-: -6.973 [-13.778; -0.167]; DM+/CAD+: -9.039 [-15.174; -2.903]), reduced left ventricular volumes (β end-diastolic, -6.323 [-9.696; -2.951]; -2.503 [-5.531; 0.526]; end-systolic, -2.905 [-4.817; -0.992]; -1.400 [-3.120; 0.320]) higher levels galectin-3 (Exponential 1.127 [1.050; 1.209]; 1.118 [1.048; 1.192]), growth differentiation factor-15 1.542 [1.360; 1.747]; 1.535 [1.370; 1.720]), along an elevated E/e' ratio 1.355 [0.462; 2.248]; 0.879 [0.067; 1.690]), compared DM-/CAD individuals (all p < 0.05). follow-up, significantly different across phenotypes p-interaction > 0.05), except more pronounced reduction GDF-15 DM+/CAD 1-month visit (p-interaction 0.03). Among participants, powerful driver biomarker irrespectively CAD. These mainly related domains inflammation diastolic function. Summary study design key findings. Abbreviations: coronary disease; mellitus; LV, ventricular; M0, baseline; M1, follow-up; M9, 9-month PICP, procollagen propeptide.
Язык: Английский
Процитировано
1
European Journal of Heart Failure, Год журнала: 2025, Номер 27(4), С. 611 - 613
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
European Journal of Heart Failure, Год журнала: 2025, Номер unknown
Опубликована: Май 24, 2025
Язык: Английский
Процитировано
0
Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 12
Опубликована: Май 27, 2025
Background Finerenone has been shown to improve outcomes in patients with heart failure (HF), encompassing those reduced (HFrEF), mildly (HFmrEF), or preserved ejection fraction (HFpEF). However, its clinical use is accompanied by notable adverse effects. This study aimed evaluate the relative risks of events associated finerenone across HF phenotypes. Methods A systematic search PubMed, Embase, and Web Science identified six randomized controlled trials involving 8,527 patients. The analysis considered hyperkalemia, hypotension, treatment-emergent (TEAEs), serious (TESAEs), treatment discontinuation due events. Results significantly increased risk hyperkalemia (RR = 2.07, 95% CI 1.77-2.44, P < 0.00001) hypotension 1.49, 1.31-1.68, compared placebo, irrespective phenotype. No significant differences were observed between placebo terms TEAEs, TESAEs, when analyzing overall population. Compared eplerenone, was a lower TEAEs 0.93, CI: 0.89-0.98) TESAEs 0.74, 0.66-0.84), similar rates. Additionally, one included suggested that may have 0.64, 0.56-0.74), 0.37, 0.25-0.54) 0.41, 0.21-0.79) spironolactone, rates 0.61, 0.29-1.30) HFrEF. Conclusion (10-25 mg) showed safety profile no discontinuation. fewer comparable Moreover, HFrEF, offer discontinuation, than hypotension.
Язык: Английский
Процитировано
0
European Journal of Heart Failure, Год журнала: 2025, Номер unknown
Опубликована: Июнь 2, 2025
Язык: Английский
Процитировано
0